GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Effective Interest Rate on Debt %

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Eucrates Biomedical Acquisition's annualized positive value of Interest Expense for the quarter that ended in Dec. 2022 was $0.00 Mil. Eucrates Biomedical Acquisition's average total debt for the quarter that ended in Dec. 2022 was $0.06 Mil. Therefore, Eucrates Biomedical Acquisition's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2022 was 0.00%.


Eucrates Biomedical Acquisition Effective Interest Rate on Debt % Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Effective Interest Rate on Debt % Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Effective Interest Rate on Debt %
- - -

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eucrates Biomedical Acquisition's Effective Interest Rate on Debt %

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eucrates Biomedical Acquisition's Effective Interest Rate on Debt % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Effective Interest Rate on Debt % falls into.



Eucrates Biomedical Acquisition Effective Interest Rate on Debt % Calculation

Eucrates Biomedical Acquisition's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2021 )+Total Debt  (A: Dec. 2022 ))/ count )
=-1  *  0/( (0+0.06)/ 1 )
=-1  *  0/0.06
=0.00 %

where

Eucrates Biomedical Acquisition's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2022 )+Total Debt  (Q: Dec. 2022 ))/ count )
=-1  *  0/( (0.063+0.06)/ 2 )
=-1  *  0/0.0615
=0.00 %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2022) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Eucrates Biomedical Acquisition  (NAS:EUCRU) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Eucrates Biomedical Acquisition Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines